Efficacy comparison between resveratrol and ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy

Abstract

Abstract: Objective To compare the efficacy between resveratrol (RES) and ursodeoxycholic acid (UDCA) in the treatment of intrahepatic cholestasis of pregnancy (ICP).Methods Seventy Sprague-Dawley (SD) rats on day 13 of pregnancy were induced ICP using 17-α ethinyl estradiol, and divided into control group, ICP group and 5 treatment groups [low-dosage RES (LRES) group, middle-dosage RES (MRES) group, high-dosage RES (HRES) group, UDCA group and UDCA combined with MRES (UDCA-MRSV) group]. Livers were collected for histological analysis using hematoxylin and eosin (HE) staining. Serum levels of total bile acid (TBA) and alanine aminotransferase (ALT) were measured before and after treatment in all 5 treatment groups. Stillbirth rate of each group was counted. Immunohistochemistry and western blot were applied for determining intrahepatic levels of silent information regulator 1 (SIRT1) and tumor necrosis factor-α (TNF-α).Results Compared with ICP group, LRES could obviously decrease TBA (31.81±15.19 umol/L, P<0.05), and MRES could obviously decrease the stillbirth rate (14.29%, P<0.05). UDCA-MRSV might synergistically reduce TBA level (27.77±7.43 umol/L, P<0.05), but with a higher rate of stillbirth (36.26%, P<0.05) than the single drug treatment. RES could enhance SIRT1 expression (P<0.05) and decrease TNF-α expression (P<0.05).Conclusion RES might be a potential option in treatment of ICP, of which effective dosage needs further investigation.

Key words: Resveratrol, Ursodeoxycholic acid, Intrahepatic cholestasis of pregnancy

LIAO E, SHAO Yong. Efficacy comparison between resveratrol and ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy[J]. Chinese Hepatolgy, 2017, 22(8): 685-689.

References

[1] Chanda D, Xie YB, Choi HS. Transcriptional corepressor SHP recruits SIRT1 histone deacetylase to inhibit LRH-1 transactivation. Nucleic Acids Res, 2010, 38: 4607-4619.
[2] Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol, 2014, 124: 120-133.
[3] Beuers U, Pusl T. Intrahepatic cholestasis of pregnancy-A heterogeneous group of pregnancy-related disorders? Hepatology, 2006, 43: 647-649.
[4] Tan LK. Obstetric cholestasis: current opinions and management. Ann Acad Med Singapore, 2003, 32: 294-298.
[5] Meng LJ, Reyes H, Palma J, et al. Effects of ursodeoxycholic acid on conjugated bile acids and progesterone metabolites in serum and urine of patients with intrahepatic cholestasis of pregnancy. J Hepatol, 1997, 27: 1029-1040.
[6] Westbrook RH, Dusheiko G, Williamson C. Pregnancy and liver disease. J Hepatol, 2016, 64: 933-945.
[7] Bacq Y, Sentilhes L, Reyes HB, et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology, 2012, 143: 1492-1501.
[8] 刘红, 刘建, 李金艳. 熊脱氧胆酸对抗乙炔雌二醇诱发孕大鼠肝内胆汁淤积的作用机制. 现代妇产科进展, 2005, 14: 229-232.
[9] Joutsiniemi T, Timonen S, Linden M, et al. Intrahepatic cholestasis of pregnancy: observational study of the treatment with low-dose ursodeoxycholic acid. BMC Gastroenterol, 2015, 15: 92.
[10] Glantz A, Marschall HU, Lammert F, et al. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology, 2005, 42: 1399-1405.
[11] Saleh MM, Abdo KR. Intrahepatic cholestasis of pregnancy: review of the literature and evaluation of current evidence. J Womens Health (Larchmt), 2007, 16: 833-841.
[12] Sinakos E, Marschall HU, Kowdley KV, et al. Bile acid changes after high‐dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology, 2010, 52: 197-203.
[13] Pozo-Guisado E, Merino JM, Mulero-Navarro S, et al. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-κB. Int J Cancer, 2005, 115: 74-84.
[14] Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science, 2000, 289: 2126-2128.
[15] Hoberg JE, Keller MD, Ramsey CS, et al. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J, 2004: 2369-2380.
[16] Kiernan R, Brès V, Ng RWM, et al. Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65. J Biol Chem, 2003, 278: 2758-2766.
[17] Li D, Wang X, Ren W, et al. High expression of liver histone deacetylase 3 contributes to high-fat-diet-induced metabolic syndrome by suppressing the PPAR-γ and LXR-α-pathways in E3 rats. Mol Cell Endocrinol, 2011, 344: 69-80.
[18] Zhang Y, Pan Y, Lin C, et al. Bile acids evoke placental inflammation by activating Gpbar1/NF-κB pathway in intrahepatic cholestasis of pregnancy. J Mol Cell Biol, 2016, 8: 530-541.
[19] Chen Z, Hu L, Lu M, et al. Resveratrol reduces matrix metalloproteinases and alleviates intrahepatic cholestasis of pregnancy in rats. Can J Physiolo Pharmacolo, 2015, 94: 402-407.